Description of use

The ArteraAI Prostate Biopsy Assay is a multimodal artificial intelligence (MMAI)-based test that leverages a unique algorithm that combines digital image and clinical data to estimate long-term clinical outcomes and predict risk appropriate treatment benefit (from short-term androgen-deprivation therapy (ST-ADT), active surveillance suitability, or abiraterone benefit). Hematoxylin and eosin (H&E)–stained slides from a prostate biopsy are scanned to create digital images. Once a pathologist reviews these digital histopathology images and confirms a prostate cancer diagnosis, the images and a limited set of clinical variables–clinical tumor stage, PSA blood test, and patient age at biopsy–are assessed by the MMAI and test results are calculated through AI-based analysis.